



## *Executive Team*

### **N. ANTHONY (TONY) COLES, M.D., M.P.H.**

#### **President, Chief Executive Officer and Member of the Board**

Dr. Coles joined Onyx in March 2008 as President, Chief Executive Officer, and a member of its Board of Directors. Prior to joining Onyx, he was President, Chief Executive Officer, and a member of the Board of Directors of NPS Pharmaceuticals, Inc. Before joining NPS Pharmaceuticals in 2005, Dr. Coles was Senior Vice President of Commercial Operations at Vertex Pharmaceuticals Incorporated, which he joined in 2002. Beginning in 1996, he held a number of executive positions while at Bristol-Myers Squibb Company, including Senior Vice President of Strategy and Policy; Senior Vice President of Marketing and Medical Affairs, Neuroscience/Infectious Diseases/Dermatology; Vice President, Western Area Sales Cardiovascular and Metabolic Business Unit for U.S. Primary Care; and Vice President, Cardiovascular Global Marketing. From 1992 until 1996, Dr. Coles also held a number of positions of increasing responsibility at Merck & Co., Inc., including Vice President of the Hypertension and Heart Failure Business Group.

Dr. Coles completed his cardiology and internal medicine training at Massachusetts General Hospital and was a research fellow at Harvard Medical School. He earned an M.D. degree from Duke University, a master's degree in public health from Harvard University, and an undergraduate degree from Johns Hopkins University. Dr. Coles currently serves as a member of the Board of Trustees for Johns Hopkins Medicine, as well as a trustee and member of the Executive Committee for the Johns Hopkins University Board of Trustees. He is also a member of the board of the Biotechnology Industry Organization (BIO) and FoldRx, Inc., a privately held biotech company in Cambridge, MA.

### **LAURA A. BREGE**

#### **Executive Vice President and Chief Operating Officer**

Laura A. Brege joined Onyx in June 2006 as Executive Vice President & Chief Business Officer. In that role, she oversaw the expansion of key corporate capabilities and strengthened Onyx's financial position by significantly adding to its cash reserves. She was promoted to her current position in October 2007 and is responsible for the sales and marketing, medical affairs, legal, business development, and compliance functions. Before joining Onyx, Ms. Brege was a general partner at Red Rock Management, a venture capital firm. Prior to Red Rock, she was the Senior Vice President and Chief Financial Officer at COR Therapeutics. Earlier in her career, Ms. Brege served as Vice President and Chief Financial Officer at Flextronics and Vice President and Treasurer of The Cooper Companies. Ms. Brege earned her undergraduate degree from Ohio University and has an MBA from the University of Chicago. Ms. Brege serves on the Board of Directors of Acadia Pharmaceuticals, Angiotech Pharmaceuticals, Inc. and Zvents, Inc.

### **MATTHEW K. FUST**

#### **Executive Vice President and Chief Financial Officer**

Matthew K. Fust joined Onyx in January 2009 as Executive Vice President and Chief Financial Officer. Prior to joining Onyx, Mr. Fust was Executive Vice President and Chief Financial Officer at Jazz Pharmaceuticals, which he joined in 2003. From 2002 until 2003, he was Chief Financial Officer at Perlegen Sciences, a biotechnology company. Previously, Mr. Fust was Senior Vice President and Chief Financial Officer at Alza Corporation where he was an Executive from 1996 until 2002. From 1991 until 1996, Mr. Fust was a Manager in the healthcare strategy practice at Anderson Consulting. Mr. Fust earned an undergraduate degree in accounting from the University of Minnesota and an MBA from the Graduate School of Business at Stanford University. He serves as a member of the Board of Directors for Sunesis Pharmaceuticals.

## **TED W. LOVE, M.D.**

### **Executive Vice President and Head of Research & Development**

Ted W. Love, M.D. joined Onyx in January 2010 as Executive Vice President and Head of Research and Development. Prior to joining Onyx, Dr. Love was President, Chief Executive Officer and Chairman of the Board of Directors at Nuvelo, which he joined in 2001. Previously, he served as Senior Vice President of Development at Theravance, Inc. Earlier in his career, Dr. Love spent six years at Genentech, Inc. in a number of senior management positions in Medical Affairs and Product Development. As Vice President of Product Development and Regulatory Affairs at Genentech, Dr. Love oversaw all drugs in development including Herceptin, Rituxan, and TNKase. He also served as Chairman of Genentech's Product Development Committee. Dr. Love earned his undergraduate degree in molecular biology from Haverford College and his medical degree at Yale Medical School. Dr. Love completed his residency and fellowship training in internal medicine and cardiology at Harvard Medical School and Massachusetts General Hospital, where he later served on the faculty. He currently serves on the Board of Directors of Affymax, Inc., Santarus, Inc., ARCA biopharma, Inc., and on the California Institute for Regenerative Medicine (CIRM) Independent Citizens' Oversight Committee.

## **MICHAEL G. KAUFFMAN, M.D., PH.D.**

### **Chief Medical Officer**

Michael G. Kauffman, M.D., Ph.D., joined Onyx in February 2010 as chief medical officer after serving as the interim chief medical officer following the acquisition of Proteolix, Inc. in November 2009. Dr. Kauffman was chief medical officer at Proteolix, after having served on their board of directors. At Proteolix, he was responsible for the clinical advancement of carfilzomib as well as ONX -912 (PR-047). Prior to joining Proteolix, Dr. Kauffman was president and chief executive officer of EPIX Pharmaceuticals, Inc. (previously Predix Pharmaceuticals, Inc.) from 2002 to 2008. From 1997 to 2002, he held a number of senior medical and program leadership positions at Millennium Pharmaceuticals, Inc. (now a subsidiary of Takeda Pharmaceutical Company), where he played a key role in the development of the proteasome inhibitor VELCADE®. Earlier in his career, he served as medical director at Biogen Corporation (now Biogen Idec). Dr. Kauffman earned his undergraduate degree in biochemistry from Amherst College and his M.D. and Ph.D in molecular biology and biochemistry from Johns Hopkins. He trained in Internal Medicine and Rheumatology at Beth Israel Deaconess Hospital and the Massachusetts General Hospital.

## **JUERGEN LASOWSKI, PH.D.**

### **Senior Vice President, Corporate Development**

Juergen Lasowski, Ph.D., joined Onyx in May 2008 as Senior Vice President of Corporate Development. Before joining Onyx, Dr. Lasowski was the Senior Vice President of Corporate Development at NPS Pharmaceuticals. Previously, Dr. Lasowski held several positions at Sanofi-Aventis and its predecessor companies, mainly Business Development and Strategy positions. Throughout his career, Dr. Lasowski has completed over 25 different business transactions and worked on three continents including North America, Europe and Asia. Dr. Lasowski earned his MBA from INSEAD, France, and his Ph.D. in organic chemistry from the University of Mainz, Germany.

## **SUZANNE M. SHEMA, J.D.**

### **Senior Vice President, General Counsel**

Suzanne M. Shema, J.D. joined Onyx in August 2009 as Senior Vice President, General Counsel. Prior to joining Onyx, Ms. Shema was Senior and General Counsel of Law and Compliance at ZymoGenetics, which she joined in 2001. Before ZymoGenetics, Ms. Shema served as General Counsel at aQuantive, Inc. She also served as Associate General Counsel at Research Corporation Technologies, Inc. Prior to Research Corporation Technologies, Ms. Shema served as Associate General Counsel at NeoRx Corporation. Earlier in her career, she served as an Associate at the law firm of Seed and Berry. Ms. Shema earned an undergraduate degree in chemistry from the University of Texas, a master's degree in chemistry from the University of Washington and a J.D. from the University of Washington.

## JUDY BATLIN

### Vice President of Organizational Learning, Development, and Human Resources

Judy Batlin has served as Onyx's Vice President of Organizational Learning, Development, and Human Resources since February 2008, and had previously served as an organization development consultant at Onyx since 2005. Ms. Batlin specializes in developing leadership competencies and overall effectiveness of teams and individual employees. She has over twenty years of experience in the biotechnology and pharmaceutical industry, and during her career has collaborated with a variety of organizations such as Acologix, Exelixis, Iconix Pharmaceuticals, Genentech, Pharmacoepia, Celera, Stanford Medical Center and Clinics, Chiron, and Berlex. Earlier in her career, Ms. Batlin served as Director of Organizational Learning, as well as Director of Staffing and Employee Relations for Chiron Corporation. Previously, she held the position of Associate Director of Human Resource Development at Berlex Laboratories.

## JULIANNA WOOD

### Vice President, Corporate Communications and Investor Relations

Julie Wood joined Onyx in May 2003 to manage internal and external communications. She has an extensive background in investor relations and communications, with a particular emphasis on the life sciences. Prior to Onyx, Ms. Wood was Senior Director of Investor Relations and Corporate Communications at Caliper Technologies Corp. She has served in a similar capacity at Sangamo BioSciences and Chiron Corporation. She earned her undergraduate degree from Stanford University and has an M.B.A. from Duke University.

# *Board of Directors*

## **N. ANTHONY (TONY) COLES, M.D.**

**President, Chief Executive Officer and Member of the Board**

Dr. Coles joined Onyx in March 2008 as President, Chief Executive Officer, and a member of its Board of Directors. Prior to joining Onyx, he was President, Chief Executive Officer, and a member of the Board of Directors of NPS Pharmaceuticals, Inc. Before joining NPS Pharmaceuticals in 2005, Dr. Coles was Senior Vice President of Commercial Operations at Vertex Pharmaceuticals Incorporated, which he joined in 2002. Beginning in 1996, he held a number of executive positions while at Bristol-Myers Squibb Company, including Senior Vice President of Strategy and Policy; Senior Vice President of Marketing and Medical Affairs, Neuroscience/Infectious Diseases/Dermatology; Vice President, Western Area Sales Cardiovascular and Metabolic Business Unit for U.S. Primary Care; and Vice President, Cardiovascular Global Marketing. From 1992 until 1996, Dr. Coles also held a number of positions of increasing responsibility at Merck & Co., Inc., including Vice President of the Hypertension and Heart Failure Business Group.

Dr. Coles completed his cardiology and internal medicine training at Massachusetts General Hospital and was a research fellow at Harvard Medical School. He earned an M.D. degree from Duke University, a master's degree in public health from Harvard University, and an undergraduate degree from Johns Hopkins University. Dr. Coles currently serves as a member of the Board of Trustees for Johns Hopkins Medicine, as well as a trustee and member of the Executive Committee for the Johns Hopkins University Board of Trustees. He is also a member of the board of the Biotechnology Industry Organization (BIO) and FoldRx, Inc., a privately held biotech company in Cambridge, MA.

## **PAUL GODDARD, PH.D.**

**Lead Director, Onyx Pharmaceuticals, Inc.**

**Chairman and Chief Executive Officer, ARYx Therapeutics, Inc.**

Paul Goddard, Ph.D. has served as a Director since February 1997. From March 2000 to March 2002, Dr. Goddard served as a consultant and advisor to Elan plc. From August 1998 to March 2000, Dr. Goddard served as President and Chief Executive Officer of Elan Pharmaceuticals, Inc., a biotechnology company and a division of Elan plc. From March 1991 to August 1998, Dr. Goddard served as Chief Executive Officer and Chairman of the Board of Neurex Corporation, a biotechnology company, until Neurex Corporation was acquired by Elan Corporation plc. Dr. Goddard is Chairman of the Board of Directors of AP Pharma and Chairman and CEO of ARYx Therapeutics, Inc. Dr. Goddard serves on the Board of Directors of Molecular Devices Corporation and Adolor Corporation. He completed his Ph.D. in the area of Etiology and Pathophysiology of colon cancer at St. Mary's Hospital, University of London.

## **ANTONIO J. GRILLO-LÓPEZ, M.D.**

**Retired Chief Medical Officer, IDEC Pharmaceuticals**

Antonio J. Grillo-López, M.D. has served as a Director since September 2002. From November 1992 to January 2001, Dr. Grillo-López served as Chief Medical Officer of IDEC Pharmaceuticals Corporation and from January 2001 to November 2003 held the position of Chief Medical Officer Emeritus of IDEC Pharmaceuticals Corporation. Dr. Grillo-López serves on the Boards of Directors of Favrilite, Inc. and Salmedix, Inc., and on the scientific advisory boards of Favrilite, Inc., Conforma Therapeutics Corporation, SuperGen, Inc., Salmedix, Inc., Seattle Genetics, Inc., Attenuon LLC and Nereus Pharmaceuticals. Dr. Grillo-López holds a B.S. and an M.D. from the University of Puerto Rico.

## MAGNUS LUNDBERG

### Chief Executive Officer, Phadia Group

Magnus Lundberg has served as a Director since June 2000. Since April 2004, Mr. Lundberg has served as President and Chief Executive Officer of Phadia Group, previously Pharmacia Diagnostics AB, a privately held diagnostic company, and formerly a division of Pfizer Inc., a pharmaceutical company. From March 1999 to April 2004, Mr. Lundberg served as President and Chief Executive Officer of Pharmacia Diagnostics AB, while it was a division of Pfizer. From September 1996 to March 1999, Mr. Lundberg served as President of both Chiron Therapeutics and Chiron Vaccines, each a division of Chiron Corporation, a biotechnology company. From 1981 to September 1996, Mr. Lundberg held various management positions at Pharmacia AB, a pharmaceutical company. Mr. Lundberg holds an M.Sc. in Biology and Biochemistry from Abo Akademi in Turku, Finland.

## CORINNE H. NEVINNY

### Corporate Vice President and General Manager CSS, Vascular & Canada Edwards Lifesciences Corporation

Ms. Nevinny has served as a Director since October 2005. She is currently Corporate Vice President and General Manager at Edwards Lifesciences Corporation, a leading cardiovascular technology company. Prior to joining Edwards in March 2003, Ms. Nevinny was Vice President and Chief Financial Officer of Tularik, Inc, a biotechnology company, for five years. From 1996 until 1998, Ms. Nevinny was Executive Director for the health care group at Warburg Dillon Read LLC, an investment bank. From 1994 to 1996, she was Senior Vice President for the health care group at PaineWebber, Inc., an investment bank. Ms. Nevinny serves on the Board of Directors of Neurocrine Biosciences, Inc., a biopharmaceutical company. Ms. Nevinny received her undergraduate degree from Stanford University and her MBA from Harvard Business School.

## WENDELL WIERENGA, PH.D.

### Executive Vice President, Research and Development, Ambit Biosciences

Wendell Wierenga, Ph.D. has served as a Director of the Company since December 1996. Since January 2007, Dr. Wierenga has served as Executive Vice President, Research and Development of Ambit Biosciences. Previously, he was Executive Vice President, Research and Development of Neurocrine Biosciences, Inc. From September 2000 to August 2003, Dr. Wierenga served as the Chief Executive Officer of Syrrx, Inc., a biotechnology company. From February 1999 to August 2000, Dr. Wierenga served as Senior , Worldwide Pharmaceutical Sciences, Technologies and Development for the Parke-Davis Pharmaceutical Research division of Warner-Lambert Company, a subsidiary of Pfizer Inc., and from 1990 to February 1999 as Senior of Research of Parke-Davis. Dr. Wierenga served as Vice President of Medtech Ventures of Warner-Lambert, a pharmaceutical company, from 1992 to 2000. Dr. Wierenga also serves on the Board of Directors of XenoPort, Inc. Dr. Wierenga holds a B.A. from Hope College and a Ph.D. in chemistry from Stanford University.

## THOMAS G. WIGGANS

### Former Chairman and Chief Executive Officer, Peplin, Inc. and Connetics Corporation

Thomas G. Wiggans has served as a Director of the Company since March 2005. Mr. Wiggans is the former Chairman and Chief Executive Officer of Peplin, Inc. Previously, he was the Chairman and Chief Executive Officer of Connetics Corporation, a specialty pharmaceutical company. Prior to Connetics, Mr. Wiggans was President and Chief Operating Officer of CytoTherapeutics, Inc., a biotechnology company. Earlier in his career, Mr. Wiggans served in various positions at Ares-Serono Group, including as President of its U.S. pharmaceutical operations and as Managing Director of its U.K. pharmaceutical operations. Before joining Ares-Serono, he held sales and marketing positions with Eli Lilly and Company. In addition, he is Chairman of the Biotechnology Institute, a non-profit educational organization, and serves on the Board of Directors of Sangamo Biosciences and Somaxon Pharmaceuticals. Mr. Wiggans received his B.S. in Pharmacy from the University of Kansas and his M.B.A. from Southern Methodist University.